为了检查当代大型队列因局限性前列腺癌接受根治性前列腺切除术的患者的生存和疾病控制结果，包括与转移相关的生存结果。我们对 2005 年至 2015 年接受根治性前列腺切除术治疗的局限性前列腺癌男性进行了一项回顾性研究退伍军人健康管理局将进行 2019 年后续行动。我们将生化复发 (BCR) 定义为 PSA ≥0.2 ng/mL。我们使用经过验证的自然语言处理编码数据集来识别偶发的转移性前列腺癌。我们使用 Kaplan-Meier 方法根据手术时间、BCR 时间和首次转移时间估计总体生存率。然后，我们使用考虑死亡竞争风险的累积发生率来估计从手术到 BCR、BCR 到转移性疾病的时间，以及不同时间点的前列腺癌特异性生存率。 在 21,992 名接受根治性前列腺切除术的男性中，我们确定了 5,951 名 (27%) 患者出现了生化不良反应。复发（BCR）。在患有 BCR 的男性中，677 名 (11%) 出现了转移。我们估计 BCR 和 BCR 后转移的 10 年累积发生率分别为 28% 和 20%。 BCR 后的中位总生存期为 14 年，10 年生存率为 70%。从转移开始，中位总生存期接近7年，10年总生存率为34%。整个队列的 10 年前列腺癌特异性生存率为 94%。在这个大型当代全国队列中，患有生化复发前列腺癌的男性的生存期比历史队列更长。在为患者提供咨询和设计临床研究时，这些更新的估计可能会更可靠地反映当前结果。版权所有 © 2023。由 Elsevier Inc. 出版。

To examine survival and disease control outcomes, including metastasis-related survival outcomes, in a large contemporary cohort of patients undergoing radical prostatectomy for localized prostate cancer.We conducted a retrospective study of men with localized prostate cancer treated with radical prostatectomy from 2005-2015 with follow up through 2019 in the Veterans Health Administration. We defined biochemical recurrence (BCR) as a PSA ≥0.2 ng/mL. We used a validated natural language processing encoded dataset to identify incident metastatic prostate cancer. We estimated overall survival from time of surgery, time of BCR, and time of first metastasis using the Kaplan-Meier method. We then estimated time from surgery to BCR, BCR to metastatic disease, and prostate-cancer specific survival from various time points using cumulative incidence considering competing risk of death.Of 21,992 men undergoing radical prostatectomy, we identified 5,951 (27%) who developed biochemical recurrence (BCR). Of men with BCR, 677 (11%) developed metastases. We estimated the 10-year cumulative incidence of BCR and metastases after BCR were 28% and 20%, respectively. Median overall survival after BCR was 14 years, with 10-year survival of 70%. From the time of metastasis, median overall survival approached 7 years, with 10-year overall survival of 34%. Prostate cancer-specific survival for the entire cohort at 10 years was 94%.In this large contemporary national cohort, survival for men with biochemically-recurrent prostate cancer is longer than historical cohorts. When counseling patients and designing clinical studies, these updated estimates may serve as more reliable reflections of current outcomes.Copyright © 2023. Published by Elsevier Inc.